Media coverage about Ligand Pharmaceuticals (NASDAQ:LGND) has trended somewhat positive recently, Accern reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ligand Pharmaceuticals earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.2048783337226 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

These are some of the news articles that may have impacted Accern’s analysis:

LGND stock opened at $254.54 on Friday. Ligand Pharmaceuticals has a fifty-two week low of $126.50 and a fifty-two week high of $261.33. The firm has a market cap of $5.37 billion, a P/E ratio of 99.04, a price-to-earnings-growth ratio of 1.77 and a beta of 0.99. The company has a quick ratio of 2.32, a current ratio of 2.34 and a debt-to-equity ratio of 0.96.

Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings results on Monday, August 6th. The biotechnology company reported $2.59 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.34 by $0.25. Ligand Pharmaceuticals had a return on equity of 25.95% and a net margin of 52.10%. The firm had revenue of $90.00 million during the quarter, compared to analysts’ expectations of $82.20 million. During the same period last year, the firm posted $0.67 EPS. The business’s revenue was up 221.4% on a year-over-year basis. equities research analysts expect that Ligand Pharmaceuticals will post 5.74 EPS for the current fiscal year.

Several equities analysts recently commented on the company. BidaskClub downgraded Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, June 13th. Craig Hallum raised their target price on Ligand Pharmaceuticals from $230.00 to $260.00 and gave the stock a “buy” rating in a research report on Tuesday, August 7th. HC Wainwright restated a “buy” rating and set a $249.00 target price on shares of Ligand Pharmaceuticals in a research report on Tuesday, August 7th. Stephens restated a “buy” rating and set a $248.00 target price on shares of Ligand Pharmaceuticals in a research report on Wednesday, August 8th. Finally, Roth Capital restated a “neutral” rating on shares of Ligand Pharmaceuticals in a research report on Wednesday, August 8th. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $208.57.

In related news, SVP Charles S. Berkman sold 19,417 shares of the firm’s stock in a transaction on Tuesday, September 4th. The stock was sold at an average price of $254.99, for a total transaction of $4,951,140.83. Following the completion of the sale, the senior vice president now directly owns 28,232 shares of the company’s stock, valued at approximately $7,198,877.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Todd C. Davis sold 9,000 shares of the firm’s stock in a transaction on Friday, August 17th. The shares were sold at an average price of $239.78, for a total value of $2,158,020.00. Following the sale, the director now directly owns 44,806 shares of the company’s stock, valued at $10,743,582.68. The disclosure for this sale can be found here. Insiders have sold a total of 102,609 shares of company stock valued at $25,501,826 over the last ninety days. Insiders own 7.80% of the company’s stock.

Ligand Pharmaceuticals Company Profile

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing and acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis and Evomela, which are used to treat multiple myeloma; Baxdela, a captisol-enabled delafloxacin-IV for the treatment of acute bacterial skin and skin structure infections; Nexterone, a captisol-enabled formulation of amiodarone; Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Carnexiv, which is indicated as replacement therapy for oral carbamazepine formulations; bazedoxifene for the treatment of postmenopausal osteoporosis; commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta for non-small cell lung cancer.

Featured Article: How Important is Technical Analysis of Stocks

Insider Buying and Selling by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with's FREE daily email newsletter.